Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Novartis expects low single-digit decline in 2026 operating profit

Novartis expects low single-digit decline in 2026 operating profit

Published by Global Banking and Finance Review

Posted on February 4, 2026

1 min read

Last updated: February 4, 2026

Novartis expects low single-digit decline in 2026 operating profit - Finance news and analysis from Global Banking & Finance Review

Tags:corporate profits financial management operating income ratio

Quick Summary

Novartis forecasts a low single-digit decline in 2026 operating profit due to competition from cheaper generic drugs like Entresto.

Novartis Anticipates Low Single-Digit Drop in 2026 Operating Profit

Novartis 2026 Profit Forecast

FRANKFURT, Feb 4 (Reuters) - Swiss drugmaker Novartis forecast a decline in 2026 operating profit in the low single-digit percentage range on Wednesday, held back by competition from cheaper copies of established products such as heart drug Entresto.

Factors Influencing Profit Decline

(Reporting by Ludwig Burger in Frankfurt and Bhanvi Satija in London; Editing by Emelia Sithole-Matarise and Linda Pasquini)

Key Takeaways

•Novartis anticipates a low single-digit decline in 2026 operating profit.
•The decline is attributed to competition from cheaper generic drugs.
•Heart drug Entresto faces significant market competition.
•The forecast was reported by Ludwig Burger and Bhanvi Satija.
•Novartis remains a key player in the pharmaceutical industry.

Frequently Asked Questions about Novartis expects low single-digit decline in 2026 operating profit

1What is operating profit?

Operating profit is the amount of money a company makes from its core business operations, excluding deductions of interest and taxes. It reflects the efficiency of the company's operations.

2What are established products?

Established products are goods or services that have been in the market for a significant period and have a stable customer base. They often face competition from newer, cheaper alternatives.

Novartis 2026 Profit Forecast

Factors Influencing Profit Decline

(Reporting by Ludwig Burger in Frankfurt and Bhanvi Satija in London; Editing by Emelia Sithole-Matarise and Linda Pasquini)

Key Takeaways

•Novartis anticipates a low single-digit decline in 2026 operating profit.

•The decline is attributed to competition from cheaper generic drugs.

•Heart drug Entresto faces significant market competition.

•The forecast was reported by Ludwig Burger and Bhanvi Satija.

•Novartis remains a key player in the pharmaceutical industry.

Frequently Asked Questions

1What is operating profit?

Operating profit is the amount of money a company makes from its core business operations, excluding deductions of interest and taxes. It reflects the efficiency of the company's operations.

2What are established products?

Established products are goods or services that have been in the market for a significant period and have a stable customer base. They often face competition from newer, cheaper alternatives.